These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39121844)

  • 1. Anti-LAG-3 boosts CD8 T cell effector function.
    Kureshi CT; Dougan M; Dougan SK
    Cell; 2024 Aug; 187(16):4144-4146. PubMed ID: 39121844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8
    Cillo AR; Cardello C; Shan F; Karapetyan L; Kunning S; Sander C; Rush E; Karunamurthy A; Massa RC; Rohatgi A; Workman CJ; Kirkwood JM; Bruno TC; Vignali DAA
    Cell; 2024 Aug; 187(16):4373-4388.e15. PubMed ID: 39121849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAGging behind no more: PD-1 has a new immunotherapy partner.
    Gunderson AJ
    Immunity; 2024 Oct; 57(10):2266-2268. PubMed ID: 39383843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3 and PD-1 synergize on CD8
    Andrews LP; Butler SC; Cui J; Cillo AR; Cardello C; Liu C; Brunazzi EA; Baessler A; Xie B; Kunning SR; Ngiow SF; Huang YJ; Manne S; Sharpe AH; Delgoffe GM; Wherry EJ; Kirkwood JM; Bruno TC; Workman CJ; Vignali DAA
    Cell; 2024 Aug; 187(16):4355-4372.e22. PubMed ID: 39121848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
    Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.
    Principe N; Phung AL; Stevens KLP; Elaskalani O; Wylie B; Tilsed CM; Sheikh F; Orozco Morales ML; Kidman J; Marcq E; Fisher SA; Nowak AK; McDonnell AM; Lesterhuis WJ; Chee J
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39343508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade.
    Hashimoto-Tane A; Bowman EP; Sakuma M; Yoneda N; Yugi K; de Waal Malefyt R; Saito T
    Front Immunol; 2024; 15():1444424. PubMed ID: 39234253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
    Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
    Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8
    Roy S; Coulon PG; Srivastava R; Vahed H; Kim GJ; Walia SS; Yamada T; Fouladi MA; Ly VT; BenMohamed L
    Front Immunol; 2018; 9():2922. PubMed ID: 30619285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
    Danahy DB; Kurup SP; Winborn CS; Jensen IJ; Harty JT; Griffith TS; Badovinac VP
    J Immunol; 2019 Aug; 203(3):725-735. PubMed ID: 31189573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
    Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
    Front Immunol; 2020; 11():576743. PubMed ID: 33519801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
    Li YQ; Chen XM; Si GF; Yuan XM
    Biomol Biomed; 2024 Apr; 24(4):764-774. PubMed ID: 38581716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
    Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.
    Chocarro L; Blanco E; Fernandez-Rubio L; Garnica M; Zuazo M; Garcia MJ; Bocanegra A; Echaide M; Johnston C; Edwards CJ; Legg J; Pierce AJ; Arasanz H; Fernandez-Hinojal G; Vera R; Ausin K; Santamaria E; Fernandez-Irigoyen J; Kochan G; Escors D
    EMBO Mol Med; 2024 Aug; 16(8):1791-1816. PubMed ID: 39030301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
    Lichtenegger FS; Rothe M; Schnorfeil FM; Deiser K; Krupka C; Augsberger C; Schlüter M; Neitz J; Subklewe M
    Front Immunol; 2018; 9():385. PubMed ID: 29535740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of the intratumor CD8
    Geels SN; Moshensky A; Sousa RS; Murat C; Bustos MA; Walker BL; Singh R; Harbour SN; Gutierrez G; Hwang M; Mempel TR; Weaver CT; Nie Q; Hoon DSB; Ganesan AK; Othy S; Marangoni F
    Cancer Cell; 2024 Jun; 42(6):1051-1066.e7. PubMed ID: 38861924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.